Document Detail

Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation.
MedLine Citation:
PMID:  11981005     Owner:  NLM     Status:  MEDLINE    
PURPOSE: Benchmark analysis of patients with chronic myeloid leukemia (CML) alive for more than 10 years after allogeneic bone marrow transplantation (BMT) including data on disease status, bone marrow reserve, long-term complications, and quality of life (QOL). PATIENTS AND METHODS: Eighty-nine patients (46 in first chronic phase, 43 in advanced phase) received an allogeneic BMT for CML during the study period. Medical outcomes and QOL of patients were analyzed retrospectively. RESULTS: Twenty-eight (31.5%) of 89 patients were alive at 10 years and included in this analysis. Thirteen (46.4%) of 28 long-term survivors never relapsed. Fifteen patients relapsed between 0.5 and 16 years after transplantation. Ten patients showed a hematologic relapse and received salvage treatment. Five patients showed transient low levels of BCR-ABL-positive cells by Southern blot with no subsequent hematologic relapse. One of the 28 patients died in blast crisis at 12 years. The most frequent long-term complications were chronic graft-versus-host disease, osteoporosis, and cataracts. Frequency of clonogenic progenitors remained persistently decreased. QOL assessment yielded lower scores in physical performance as compared with an age-matched normative population, whereas social functioning was equivalent. A high degree of satisfaction was noted with interpersonal relationships. CONCLUSION: Patients with CML surviving their BMT long term do well in terms of medical outcomes. A constant rate of relapse was noted, with a high salvage rate of affected patients, suggesting the need for lifelong monitoring. QOL is perceived as good, particularly as related to social functioning; however, it is inferior to a normative population with regard to physical performance.
T L Kiss; M Abdolell; N Jamal; M D Minden; J H Lipton; H A Messner
Related Documents :
14560785 - Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and...
12612815 - The hand in smith-magenis syndrome (deletion 17p11.2): evaluation by metacarpophalangea...
7042075 - Veno-occlusive disease of the liver after high-dose mitomycin c therapy and autologous ...
8392885 - Interstitial pneumonitis after bmt: 15 years experience in a single institution.
15774295 - Standard variables fail to identify patients who will not respond to fluid resuscitatio...
1427445 - Early response to alpha interferon in a patient affected by hairy cell leukemia.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  20     ISSN:  0732-183X     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2002 May 
Date Detail:
Created Date:  2002-04-30     Completed Date:  2002-05-28     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2334-43     Citation Subset:  IM    
Bone Marrow Transplant Service, Department of Medical Oncology and Hematology, Princess Margaret Hospital/University Health Network, Toronto, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blotting, Southern
Bone Marrow Transplantation*
Chi-Square Distribution
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / psychology*,  therapy*
Middle Aged
Outcome Assessment (Health Care)*
Quality of Life*
Retrospective Studies
Reverse Transcriptase Polymerase Chain Reaction
Survival Analysis
Transplantation, Homologous

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Treatment of Waldenström's macroglobulinemia with rituximab.
Next Document:  Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial eval...